Fulcrum Therapeutics annual operating margin
2020
2021
2022
2023
2024
Fulcrum Therapeutics's operating margin was −27.37% for fiscal 2024.
View full Fulcrum Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −27.37% | +3917.87 pp |
| 2023 | 2023-12-31 | −3,945.24% | −2170.39 pp |
| 2022 | 2022-12-31 | −1,774.85% | −1351.88 pp |
| 2021 | 2021-12-31 | −422.97% | +388.67 pp |
| 2020 | 2020-12-31 | −811.64% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2024 | 2024-06-30 | 65.62% | +9536.80 pp |
| Q4 2023 | 2023-12-31 | −3,213.78% | +869.87 pp |
| Q3 2023 | 2023-09-30 | −3,615.28% | −1556.53 pp |
| Q2 2023 | 2023-06-30 | −3,101.36% | −1282.29 pp |
| Q1 2023 | 2023-03-31 | −9,471.19% | −8468.18 pp |
| Q4 2022 | 2022-12-31 | −4,083.65% | −3617.87 pp |
| Q3 2022 | 2022-09-30 | −2,058.75% | −1637.88 pp |
| Q2 2022 | 2022-06-30 | −1,819.08% | −1369.82 pp |
| Q1 2022 | 2022-03-31 | −1,003.01% | −647.13 pp |
| Q4 2021 | 2021-12-31 | −465.78% | −44.78 pp |
| Q3 2021 | 2021-09-30 | −420.87% | +612.89 pp |
| Q2 2021 | 2021-06-30 | −449.26% | +346.94 pp |
| Q1 2021 | 2021-03-31 | −355.88% | +2150.26 pp |
| Q4 2020 | 2020-12-31 | −420.99% | — |
| Q3 2020 | 2020-09-30 | −1,033.77% | — |
| Q2 2020 | 2020-06-30 | −796.20% | — |
| Q1 2020 | 2020-03-31 | −2,506.13% | — |
Across the available reported history, Fulcrum Therapeutics's operating margin increased from −3,945.24% to −27.37%, a change of +3917.87 percentage points. The latest reported quarter, Q2 2024, shows 65.62%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Fulcrum Therapeutics filings at SEC.gov ↗